Recruiting
Phase 1

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

Sponsor:

Iovance Biotherapeutics, Inc.

Code:

NCT06566092

Conditions

Soft Tissue Sarcoma

Primary Central Nervous System Carcinoma

Melanoma

Rhabdomyosarcoma

Ewing Sarcoma

Eligibility Criteria

Sex: All

Age: 6 - 21

Healthy Volunteers: Not accepted

Interventions

LN-145/LN-144

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information